FY2024 EPS Estimates for Quanterix Cut by Leerink Partnrs

Quanterix Co. (NASDAQ:QTRX) – Equities research analysts at Leerink Partnrs lowered their FY2024 EPS estimates for Quanterix in a research note issued to investors on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now forecasts that the company will post earnings per share of ($0.98) for the year, down from their previous forecast of ($0.94). The consensus estimate for Quanterix’s current full-year earnings is ($0.94) per share. Leerink Partnrs also issued estimates for Quanterix’s Q4 2024 earnings at ($0.27) EPS, Q1 2025 earnings at ($0.58) EPS, Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.26) EPS, FY2025 earnings at ($1.33) EPS and FY2026 earnings at ($0.89) EPS.

Quanterix (NASDAQ:QTRX) last released its quarterly earnings results on Monday, December 23rd. The company reported ($0.22) earnings per share (EPS) for the quarter. Quanterix had a negative net margin of 30.12% and a negative return on equity of 11.74%.

Separately, TD Cowen increased their target price on shares of Quanterix from $13.50 to $16.00 and gave the stock a “hold” rating in a research report on Wednesday, November 13th.

Quanterix Stock Performance

QTRX stock opened at $10.02 on Thursday. Quanterix has a 52 week low of $8.21 and a 52 week high of $29.70. The company’s 50-day simple moving average is $11.02 and its 200 day simple moving average is $12.46. The company has a market capitalization of $385.97 million, a PE ratio of -9.45 and a beta of 1.33.

Institutional Trading of Quanterix

A number of institutional investors and hedge funds have recently made changes to their positions in the company. American Century Companies Inc. raised its position in Quanterix by 14.5% during the second quarter. American Century Companies Inc. now owns 56,145 shares of the company’s stock valued at $742,000 after purchasing an additional 7,118 shares in the last quarter. Envestnet Asset Management Inc. raised its holdings in shares of Quanterix by 2,261.8% during the 2nd quarter. Envestnet Asset Management Inc. now owns 209,731 shares of the company’s stock worth $2,771,000 after buying an additional 200,851 shares in the last quarter. Hsbc Holdings PLC lifted its position in shares of Quanterix by 34.7% during the 2nd quarter. Hsbc Holdings PLC now owns 12,738 shares of the company’s stock worth $164,000 after buying an additional 3,279 shares during the last quarter. XTX Topco Ltd acquired a new stake in Quanterix in the second quarter valued at about $307,000. Finally, Canada Pension Plan Investment Board bought a new position in Quanterix in the second quarter valued at about $140,000. Institutional investors own 86.48% of the company’s stock.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.